Vor Bio Stock Slides on Public Offering

Dow Jones

2025/11/11

By Kelly Cloonan

Shares of Vor Bio declined after the company shared plans for a public offering of $100 million of its common stock.

The stock fell 26% to $13.90 in after-hours trading on Monday. Shares are down 15% this year through market close.

Vor Bio granted underwriters a 30-day option to purchase up to an additional $15 million shares of its common stock units to cover over-allotments, according to a filing with the Securities and Exchange Commission on Monday.

The biotechnology company did not disclose the number of units or price it plans to sell them for, or its expected net proceeds.

It plans to use the proceeds to advance clinical development for telitacicept, a treatment for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

November 10, 2025 18:39 ET (23:39 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582842381"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582842381\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582842381?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 07:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582842381","market":"other","top_or_hot":-1,"title":"Vor Bio Stock Slides on Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Vor Bio declined after the company shared plans for a public offering of $100 million of its common stock. \n</p>\n<p>\n  The stock fell 26% to $13.90 in after-hours trading on Monday. Shares are down 15% this year through market close. \n</p>\n<p>\n  Vor Bio granted underwriters a 30-day option to purchase up to an additional $15 million shares of its common stock units to cover over-allotments, according to a filing with the Securities and Exchange Commission on Monday. \n</p>\n<p>\n  The biotechnology company did not disclose the number of units or price it plans to sell them for, or its expected net proceeds. \n</p>\n<p>\n  It plans to use the proceeds to advance clinical development for telitacicept, a treatment for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 18:39 ET (23:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vor Bio Stock Slides on Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVor Bio Stock Slides on Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-11 07:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Vor Bio declined after the company shared plans for a public offering of $100 million of its common stock. \n</p>\n<p>\n  The stock fell 26% to $13.90 in after-hours trading on Monday. Shares are down 15% this year through market close. \n</p>\n<p>\n  Vor Bio granted underwriters a 30-day option to purchase up to an additional $15 million shares of its common stock units to cover over-allotments, according to a filing with the Securities and Exchange Commission on Monday. \n</p>\n<p>\n  The biotechnology company did not disclose the number of units or price it plans to sell them for, or its expected net proceeds. \n</p>\n<p>\n  It plans to use the proceeds to advance clinical development for telitacicept, a treatment for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 18:39 ET (23:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582842381","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582842381","pubTimestamp":1762817940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vor Bio declined after the company shared plans for a public offering of $100 million of its common stock.The stock fell 26% to $13.90 in after-hours trading on Monday. Shares are down 15% this year through market close.Vor Bio granted underwriters a 30-day option to purchase up to an additional $15 million shares of its common stock units to cover over-allotments, according to a filing with the Securities and Exchange Commission on Monday.The biotechnology company did not disclose the number of units or price it plans to sell them for, or its expected net proceeds.It plans to use the proceeds to advance clinical development for telitacicept, a treatment for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VOR":"Vor Biopharma Inc."},"translate_title":"Vor Bio股票因公开发行而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOR":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Vor Bio declined after the company shared plans for a public offering of $100 million of its common stock. \n\n\n  The stock fell 26% to $13.90 in after-hours trading on Monday. Shares are down 15% this year through market close. \n\n\n  Vor Bio granted underwriters a 30-day option to purchase up to an additional $15 million shares of its common stock units to cover over-allotments, according to a filing with the Securities and Exchange Commission on Monday. \n\n\n  The biotechnology company did not disclose the number of units or price it plans to sell them for, or its expected net proceeds. \n\n\n  It plans to use the proceeds to advance clinical development for telitacicept, a treatment for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 18:39 ET (23:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}